Details for Patent: 9,850,230
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,850,230 protect, and when does it expire?
Patent 9,850,230 protects BRAFTOVI and is included in one NDA.
This patent has seventy-four patent family members in forty-nine countries.
Summary for Patent: 9,850,230
Title: | Compounds and compositions as protein kinase inhibitors |
Abstract: | The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. |
Inventor(s): | Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA) |
Assignee: | Array BioPharma, Inc. (Boulder, CO) |
Application Number: | 15/179,644 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,850,230
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF MELANOMA WITH A BRAF MUTATION | See Plans and Pricing | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF MELANOMA WITH A BRAF MUTATION | See Plans and Pricing | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY | See Plans and Pricing | ||||
Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,850,230
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 077975 | See Plans and Pricing | |||
Australia | 2010286569 | See Plans and Pricing | |||
Brazil | 112012004453 | See Plans and Pricing | |||
Canada | 2771775 | See Plans and Pricing | |||
Chile | 2012000340 | See Plans and Pricing | |||
China | 102725283 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |